Skip to main content
Premium Trial:

Request an Annual Quote

Natera Launches $250M Follow-On Stock Offering at $55 Per Share

NEW YORK – Natera on Thursday announced a $250 million public offering of its common stock. The Austin, Texas-based company aims to sell 4,550,000 shares of common stock at a price of $55 per share.

The offering is expected to close on Sept. 11, subject to customary closing conditions.

Natera also granted the underwriters a 30-day option to purchase up to an additional 682,500 shares at the public offering price, minus underwriting discounts and commissions.

Baird is acting as lead manager for the offering, with Morgan Stanley, Goldman Sachs, TD Cowen, and Piper Sandler acting as joint bookrunning managers. Additionally, Raymond James and Craig-Hallum are acting as co-managers.

The offering comes less than a year after a similar stock offering that raised approximately $433 million.

As of June 30, Natera held approximately $381 million in cash, cash equivalents, and restricted cash and nearly $355 million in short-term investments. The firm had raised its revenue guidance last month on the back of strong test volume growth and a promising reimbursement outlook.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.